News tagged with oseltamivir
Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore ...
Diseases, Conditions, Syndromes Apr 17, 2013 | not rated yet | 0
(HealthDay)—With the height of flu season here, the U.S Food and Drug Administration warns consumers to avoid fraudulent products that claim to prevent, treat or cure the flu.
Medications Feb 04, 2013 | not rated yet | 0
(HealthDay)—Tamiflu (oseltamivir) can now be given to children as young as 2 weeks old under an expanded approval announced Friday by the U.S. Food and Drug Administration.
Medications Dec 22, 2012 | not rated yet | 2
Early use of antiviral medications may help prevent lung failure in children with the flu, reduce hospitalizations
(Medical Xpress)—Children hospitalized for the flu are much less likely to require breathing support from a mechanical ventilator if they receive antiviral drugs like oseltamivir (Tamiflu) as soon as possible after admission, ...
Diseases, Conditions, Syndromes Nov 08, 2012 | not rated yet | 0
In an open letter to company director, Professor Sir John Bell, she says: "Billions of pounds of public money have been spent on [Tamiflu] and yet the evidence on its effectiveness and safety remains hidden from appropriate ...
Medications Oct 30, 2012 | not rated yet | 0
For the nearly 62 million Americans infected with influenza each year, oeseltamivir, commonly called Tamiflu, promises to offer relief. New research from the University of Georgia finds the medication may not have all of ...
Medications Oct 26, 2012 | 4 / 5 (2) | 1 |
(Medical Xpress)—In developed countries people over 65 years old are the most likely to die from an influenza outbreak and people in nursing homes, where the virus is difficult to control, are especially vulnerable.
Diseases, Conditions, Syndromes Oct 18, 2012 | not rated yet | 0 |
Scientists have created versions of the H5N1 bird flu that spread easily among mammals through droplets in sneezes and have concluded that the deadly virus could trigger a global pandemic in humans.
Diseases, Conditions, Syndromes Jun 22, 2012 | 4.2 / 5 (6) | 0 |
The full clinical study reports of drugs that have been authorized for use in patients should be made publicly available in order to allow independent re-analysis of the benefits and risks of such drugs, according to leading ...
Medications Apr 10, 2012 | not rated yet | 0
Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages ...
Medications Jan 18, 2012 | not rated yet | 0
The flu season is still young in the United States and the rest of the Northern Hemisphere, but Australia wrapped up its flu season months ago, and public health officials there have some disturbing news to report: The version ...
Diseases, Conditions, Syndromes Dec 29, 2011 | 5 / 5 (2) | 0
In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.
Diseases, Conditions, Syndromes Sep 14, 2011 | not rated yet | 0 |
Oseltamivir is the weapon of choice for preventing influenza infection from taking hold, but like any other drug, it also has the potential for adverse effects. Children in particular are susceptible ...
Medical research Sep 09, 2011 | 5 / 5 (1) | 0
Oseltamivir INN ( /ɒsəlˈtæmɨvɪər/), an antiviral drug, slows the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell; median time to symptom alleviation is reduced by 0.5–1 day. The drug is sold under the trade name Tamiflu, and is taken orally in capsules or as a suspension. It has been used to treat and prevent influenza A virus and influenza B virus infection in over 50 million people since 1999.
Oseltamivir is a prodrug, a (relatively) inactive chemical which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active neuraminidase inhibitor commercially developed. It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences, and is currently marketed by Hoffmann–La Roche (Roche). In Japan, it is marketed by Chugai Pharmaceutical Co., which is more than 50% owned by Roche.
As of December 2010[update], the World Health Organization (WHO) reported 314 samples of the prevalent 2009 pandemic H1N1 flu tested worldwide have shown resistance to oseltamivir.
For more information about Oseltamivir, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.